Latest Share Based Payments News

Entertainment Rewards Ltd reported a 12.7% increase in operating revenue for FY2025, driven by growth in key segments, but posted a wider net loss of $9.7 million amid higher expenses and a major convertible loan amendment.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

De.mem Limited reported a 19.7% increase in revenue to $13.96 million for the half-year ended June 2025, alongside a 42% reduction in net loss and its first positive adjusted EBITDA in years. Strategic acquisitions and expansion into Asian domestic markets underpin the company’s improving financial health.

X2M Connect Limited reported a $12.1 million loss for FY25, driven by a 43% revenue drop amid a softer South Korean market and the strategic exit from China. Despite cost cuts and improved margins, the company’s adjusted EBITDA loss widened, prompting a $5.4 million capital raise to shore up its balance sheet.

Greatland Resources Limited has reported a robust unaudited FY2025 result, generating $337.3 million net profit after tax from seven months of Telfer gold-copper mine operations, alongside a successful ASX listing and strong cash flow.

Swoop Holdings reported a 19.8% increase in revenue to $106.5 million for FY25, driven by organic growth and new contracts, but posted a wider net loss of $6.95 million. The company is reshaping its portfolio with divestments and major fibre network projects in Greater Melbourne.

Urbanise.com Ltd reported a solid FY2025 with 12.7% growth in Annual Recurring Revenue, underpinned by a strategic partnership with National Australia Bank that includes a 15% equity stake. The company strengthened its cash position and is poised for a new integrated payments solution launch in 2026.

CurveBeam AI Limited posted a strong 85% increase in revenue to $12.1 million for FY25, alongside a reduced net loss of $16.8 million. Despite operational improvements and a recent $11.58 million capital raise, the company flags material uncertainty over its ability to continue as a going concern.

Platinum Asset Management reported a sharp 86% drop in profit for FY25, driven by a 39% decline in funds under management amid sustained outflows and investment challenges. The company announced a transformative merger with L1 Capital, aiming to create a $16.5 billion asset manager.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.